2.45%
-6.58%
-10.58%
-27.85%
-32.51%
-45.88%
21.16%
AI Spotlight on VETO
Company Description
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region.It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs.The company was founded in 1933 and is headquartered in Lure, France.
Vetoquinol SA is a subsidiary of Soparfin SCA.
Market Data
| Last Price | 71 |
| Change Percentage | 2.45% |
| Open | 71 |
| Previous Close | 69.3 |
| Market Cap ( Millions) | 840 |
| Volume | 16846 |
| Year High | 106.2 |
| Year Low | 63.6 |
| M A 50 | 74.34 |
| M A 200 | 88.1 |
Financial Ratios
| FCF Yield | 8.60% |
| Dividend Yield | 1.20% |
| ROE | 8.81% |
| Debt / Equity | 3.85% |
| Net Debt / EBIDTA | -152.26% |
| Price To Book | 1.55 |
| Price Earnings Ratio | 17.84 |
| Price To FCF | 11.63 |
| Price To sales | 1.56 |
| EV / EBITDA | 7.49 |
News
- Jan -30 - Vetoquinol: Annual Sales 2024
- Jan -15 - Vetoquinol: 2025 Calendar of Financial Communication
- Oct -30 - Vetoquinol: Sales at End September 2024
- Oct -16 - VETOQUINOL CANADA ANNOUNCES THE LAUNCH OF FLEXADIN® ESSENTIAL, AN EVOLUTION OF THE FLEXADIN LINE
- Sep -12 - Vetoquinol: 2024 Half-year Results
- Apr -29 - Vetoquinol: Sales 1st Quarter 2024: €134M
- Apr -24 - Vetoquinol: Availability of the 2023 Universal Registration Document
- Mar -20 - Vetoquinol: 2023 Annual Results
- Jan -24 - Vetoquinol: Annual Sales 2023: €529 Million
- Jan -03 - Vetoquinol: 2024 Calendar of Financial Communication
- Oct -26 - Vetoquinol: Sales 3rd Quarter 2023
- Oct -09 - Vetoquinol: Announcement of the Availability of the Half-Year Financial Report to June 30, 2023
- Sep -13 - In 2023, Vetoquinol Celebrates Its 90th Anniversary
- Sep -07 - Vetoquinol: 2023 Half-Year Results
- Jul -12 - A. O. Smith to Hold Second Quarter Conference Call on July 27, 2023
- May -25 - 3rd Generation Appointed Chairman of the Board of Directors of Vetoquinol SA
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pets
Expected Growth : 3.5 %
What the company do ?
Pets from Vetoquinol SA refers to a range of animal health products and services provided by Vetoquinol, a global animal health company, to improve the health and well-being of pets.
Why we expect these perspectives ?
Vetoquinol SA's 3.5% growth in the Pets segment is driven by increasing pet humanization, rising demand for premium pet care products, and growing awareness of animal health. Additionally, the company's strategic expansion into new markets, innovative product launches, and strong distribution networks contribute to its growth momentum.
Segment n°2 -> Livestock
Expected Growth : 4.5 %
What the company do ?
Livestock from Vetoquinol SA refers to a range of animal health products and solutions for farmers and veterinarians to improve animal welfare and productivity.
Why we expect these perspectives ?
Vetoquinol SA's Livestock segment growth of 4.5% is driven by increasing demand for animal health products, expansion into emerging markets, and strategic partnerships. Rising awareness of animal welfare and growing adoption of precision livestock farming also contribute to growth. Additionally, the company's focus on innovation and R&D investments in parasiticides and vaccines support revenue expansion.
Vetoquinol Sa Products
| Product Range | What is it ? |
|---|---|
| Cerenia | A medication used to prevent and treat motion sickness in dogs |
| Upcard | A medication used to treat heart failure in dogs |
| Zylkène | A natural product used to calm and reduce anxiety in dogs and cats |
| Eqvalan | A medication used to treat internal parasites in horses |
| Solensia | A medication used to treat osteoarthritis in cats |
| Imizol | A medication used to treat coccidiosis in cattle |
Vetoquinol SA's Porter Forces
Threat Of Substitutes
The threat of substitutes for Vetoquinol SA is moderate due to the presence of alternative products and services in the animal health industry.
Bargaining Power Of Customers
The bargaining power of customers is low for Vetoquinol SA, as the company has a diverse customer base and is not heavily dependent on a single customer.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate for Vetoquinol SA, as the company relies on a few key suppliers for raw materials and services.
Threat Of New Entrants
The threat of new entrants is high for Vetoquinol SA, as the animal health industry is attractive and has low barriers to entry.
Intensity Of Rivalry
The intensity of rivalry is high for Vetoquinol SA, as the animal health industry is highly competitive and fragmented.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 3.24% |
| Debt Cost | 7.21% |
| Equity Weight | 96.76% |
| Equity Cost | 8.48% |
| WACC | 8.44% |
| Leverage | 3.34% |
Vetoquinol SA : Quality Control
Vetoquinol SA passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PSG.DE | PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream … |
| SECARE.ST | Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the … |
| FAGR.BR | Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it … |
| RJF.MC | Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include … |
| BOI.PA | Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Reig Jofre
A-Score
1-Year Total Return ->
🥈
Fagron
A-Score
1-Year Total Return ->
🥉
PharmaSGP Holding
A-Score
1-Year Total Return ->
4
Boiron
A-Score
1-Year Total Return ->
5
Vetoquinol
A-Score
1-Year Total Return ->
6
